a b c
d e f
g h i
j k l
m n o
p q r s
t u v
w x y z
a b c
d e f
g h i
j k l
m n o
p q r s
t u v
w x y z
|
||
|
Product |
Code |
Section |
|
CA19-9 (Sialyl Lewisa) |
NCL-CA19-9 |
Tumour Markers |
|
CA19-9 (Sialyl Lewisa) (Liquid Primary Antibody) |
NCL-L-CA19-9 |
Tumour Markers |
|
CA50 (Carcinoma Associated Mucin Antigen) |
NCL-CA50 |
Tumour Markers |
|
CA125 (Ovarian Cancer Antigen) |
NCL-CA125 |
Tumour Markers |
|
CA125 (Ovarian Cancer Antigen) (Liquid Primary Antibody) |
NCL-L-CA125 |
Tumour Markers |
|
CA125 (Ovarian Cancer Antigen) (Ready to Use) |
RTU-CA125 |
Tumour Markers |
|
CA242 (Tumour Associated Mucin Antigen) |
NCL-CA242 |
Tumour Markers |
|
CAK (cdk-activating kinase) |
NCL-CAK |
Cell Cycle Associated Markers |
|
Calbindin |
NCL-CALBINDIN |
Neural Tissue and Tumour Markers |
|
Calcitonin |
NCL-CALp |
Hormones |
|
Caldesmon |
NCL-CALD |
Special Interest |
|
Calicivirus (feline) (capsid protein) |
NCL-1G9 |
Microbiology/Virology |
|
CALLA (CD10) |
NCL-CD10-270 |
Cluster Differentiation Markers |
|
CALLA (CD10) (Liquid Primary Antibody) |
NCL-L-CD10-270 |
Cluster Differentiation Markers |
|
CALLA (CD10) (Ready to Use) |
RTU-CD10-270 |
Cluster Differentiation Markers |
|
CALLA (CD10) |
NCL-CD10 |
Cluster Differentiation Markers |
|
Calpain |
NCL-CALP-2C4 |
Muscle Disease |
|
Calpain |
NCL-CALP-11B3 |
Muscle Disease |
|
Calpain |
NCL-CALP-12A2 |
Muscle Disease |
|
Calponin (Basic) |
NCL-CALPONIN |
Small and Intermediate Filaments |
|
Calponin (Basic) |
NCL-CALPONIN-B |
Small and Intermediate Filaments |
|
Calretinin |
NCL-CALRETININ |
Special Interest |
|
Calretinin (Liquid Primary Antibody) |
NCL-L-CALRETININ |
Special Interest |
|
Calretinin (Ready to Use) |
RTU-CALRETININ |
Special Interest |
|
Calretinin and Mesothelin Antibodies (duo pack) |
NCL-MESO/CALRETININ |
Tumour Markers |
|
Campylobacter jejuni |
NCL-C-JEJUNI |
Microbiology/Virology |
|
Carboxypeptidase M |
NCL-CPMm |
Special Interest |
|
Carboxypeptidase M |
NCL-CPMp |
Special Interest |
|
Carcinoembryonic Antigen (CD66e) |
NCL-CEA |
Tumour Markers |
|
Carcinoembryonic Antigen (CD66e) |
NCL-CEA-2 |
Tumour Markers |
|
Carcinoembryonic Antigen (CD66e) (Liquid Primary Antibody) |
NCL-L-CEA-2 |
Tumour Markers |
|
Carcinoembryonic Antigen (CD66e) (Ready to Use) |
RTU-CEA-2 |
Tumour Markers |
|
Carcinoma Associated Mucin Antigen (CA50) |
NCL-CA50 |
Tumour Markers |
|
CAS (Cellular Apoptosis Susceptibility Protein) |
NCL-CAS |
Cell Cycle Associated Markers |
|
Caspase-2 |
NCL-CASP-2 |
Cell Cycle Associated Markers |
|
Caspase-3 (CPP32) |
NCL-CPP32 |
Cell Cycle Associated Markers |
|
Caspase-3 (CPP32) |
NCL-CPP32p |
Cell Cycle Associated Markers |
|
Caspase 8 |
NCL-CASP-8 |
Cell Cycle Associated Markers |
|
Catenin, Alpha |
NCL-A-CAT |
Cellular Adhesion Molecules |
|
Catenin, Beta |
NCL-B-CAT |
Cellular Adhesion Molecules |
|
Catenin, Gamma |
NCL-G-CAT |
Cellular Adhesion Molecules |
|
Cathepsin D |
NCL-CDm |
Hormone Receptors and Estrogen Regulated Proteins |
|
Cathepsin D Kit |
NCL-CathD-Paraffin |
Immunohistochemistry Systems |
|
Cathepsin G |
NCL-CATH-G |
Special Interest |
|
Cathepsin L |
NCL-CATH-L |
Special Interest |
|
CCK-8 (Cholecystokinin) |
NCL-CCK-8p |
Hormones |
ca-cc • 